Joan R Butterton MD
Infectious Disease
Assistant Clinical Professor of Medicine, Massachusetts General Hospital
Join to View Full Profile
55 Fruit StBrb 5Boston, MA 02114
Phone+1 617-768-8730
Fax+1 617-768-8731
Are you Dr. Butterton?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joan Butterton, MD is an internist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is an Assistant Clinical Professor of Medicine at Massachusetts General Hospital.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 1988 - 1994- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1985 - 1988
Harvard Medical SchoolClass of 1985
Certifications & Licensure
MA State Medical License 1987 - 2023
Publications & Presentations
PubMed
- Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for...Ignacio Martin-Loeches, Jean-François Timsit, Marin H Kollef, Richard G Wunderink, Nobuaki Shime
The Journal of Antimicrobial Chemotherapy. 2022-03-31 - 1076 citationsMolnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez
The New England Journal of Medicine. 2022-02-10 - 55 citationsPhase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, Anna Nikolaevna Galustyan, Dany Badibanga Musungaie
NEJM Evidence. 2022-02-01
Press Mentions
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 InfectionDecember 6th, 2021- Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1November 18th, 2021
- Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021July 20th, 2021
- Join now to see all
